Study #2022-0980
A phase 2/3 randomized, controlled study of CTX-009 in combination with Paclitaxel versus Paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior Systemic Chemotherapy Regimen
MD Anderson Study Status
Not Accepting
Treatment Agent
CTX-009, Paclitaxel
Description
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Study phase:
Phase II/III
Physician name:
Ian Hu
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-363-0789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.